If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D






SCHEDULE 13D


 
Young Pharmaceuticals, Inc.
 
Signature:/s/ John E. Kulesza
Name/Title:President
Date:11/16/2026
CUSIP No. 05479L302
 
 
Schedule A
 
Directors and Officers of Young Pharmaceuticals, Inc.
 
Name
Principal Occupation
Principal Business Address
Citizenship
John E. Kulesza
President and Director
105 Progress Drive
Wethersfield CT 06109
United States of America
Peter Pekarek Kostka
Chief Financial Officer and Director
105 Progress Drive
Wethersfield CT 06109
United States of America
Shylah Cyr
Secretary
105 Progress Drive
Wethersfield CT 06109
United States of America